Results 251 to 260 of about 124,717 (304)

Leveraging Synergy: A Review of the Therapeutic Potential of SN-38 and Immune Checkpoint Blockade in Breast and Prostate Cancer Treatment. [PDF]

J Pers Med
Adekiya TA, Adesina SK.
europepmc   +1 more source

Xanthatin Targets CISD1 to Drive Ferroptosis and Mitophagy as a Dual Anticancer Strategy in Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
Triple‐negative breast cancer has a poor prognosis. Xanthatin directly targets and degrades CISD1, triggering ferroptosis through iron dysregulation. The concurrently activated mitophagy synergistically amplifies ferroptotic cell death. Xanthatin also demonstrates potent in vivo anti‐tumor efficacy with minimal toxicity, highlighting its therapeutic ...
Qinwen Liu, Haojie Chen, Xiang Li, Jingxin Liu, Yiwen Li, Zhenyi Shi, Shenshen Guo, Qingfeng Du, Aiping Lu, Daogang Guan   +9 more
wiley   +1 more source

Reinvigorating CD8⁺ T cells through ADRB1 blockade using copper-propranolol nanoparticles for enhanced immune checkpoint blockade therapy. [PDF]

J Nanobiotechnology
Weng B, Zhu N, Li H, Ding L, Wu Y, Chen Y, Xi Y, Lin L, Chen J, Xin L, Ye J, Hu Y, Li G, Guo W.   +13 more
europepmc   +1 more source

Dual Bcl-2/Bcl-xl inhibition via AZD0466 combines with immune checkpoint blockade to enhance anti-tumour activity. [PDF]

Cell Death Dis
Newman DM, Andersen CL, Cluse LA, Newbold A, Fraser P, Legg BWC, Xu LK, Mele DA, Johnstone RW.   +8 more
europepmc   +1 more source

Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trial. [PDF]

Nat Commun
Ray-Coquard I, Kaminsky-Forrett MC, Ohkuma R, de Montfort A, Joly F, Treilleux I, Ghamry-Barrin S, Bello-Roufai D, Saintigny P, Angelergues A, Michon L, Hardy-Bessard AC, Attignon V, Auclair J, Chemin G, Lainé A, Péré H, Veyer D, Savoye AM, Berthet J, Caux C, Lecuru F, Dubois B, Bétrian S.   +23 more
europepmc   +1 more source

Multimodal glioma immunotherapy combining TLR9-targeted STAT3 antisense oligodeoxynucleotides with PD1 immune checkpoint blockade. [PDF]

Neuro Oncol
Hung CY, Kang EY, Jacek K, Yu C, Zhang X, Zhu Y, Aftabizadeh M, Wong RA, Badie B, Świderski P, Kamińska B, Alizadeh D, Heimberger AB, Brown CE, Kortylewski M.   +14 more
europepmc   +1 more source

Emotional distress impairs immune checkpoint blockade efficacy in recurrent high-grade glioma: Insights from tumor in situ fluid analysis. [PDF]

Neurooncol Adv
Wang D, Zhang J, Liu G, Bu C, Wei S, Li M, Lv G, Sheng Z, Mei J, Yan Z, Gao Y, Zhao R, Shi Y, Wang M, Bu X.   +14 more
europepmc   +1 more source

Improving the efficacy of anti-SSEA4 antibody in pancreatic cancer immunotherapy with glyco-optimization and immune checkpoint blockade. [PDF]

Proc Natl Acad Sci U S A
Chuang PK, Chung C, Liao KS, Wong CH.
europepmc   +1 more source